Overview

The Gene Technology Act 2000 was enacted to provide a regulatory framework for the safe handling, use, and release of genetically modified organisms in Australia. The Act aims to protect human health and the environment while facilitating the development and use of gene technology. The Gene Technology Regulator, established under this Act, is responsible for assessing applications and managing the risks associated with gene technology activities. This includes clinical trials of genetically modified organisms such as bacteriophages for medical treatments. The policy objective of the Act is to ensure that gene technology activities are conducted in a manner that safeguards public health and the environment, whilst promoting innovation and research. The Parliament of Australia enacted this legislation to address the need for a comprehensive regulatory system to manage the potential risks associated with the use of genetically modified organisms.

Scope and Application

The proposed clinical trial for the treatment of mycobacterial infections using genetically modified bacteriophages, as outlined in the Gene Technology Regulation 2000, applies to the Western Sydney Local Health District (WSLHD) and the individuals who will participate in the trial. This Act extends to all gene technology activities in Australia, including clinical trials that involve the intentional release of genetically modified organisms into the environment or their use in medical treatments. The legislation applies to any entity proposing to conduct such trials, requiring them to submit a detailed Risk Assessment and Risk Management Plan (RARMP) to the Gene Technology Regulator. The trial itself is geographically confined to clinical trial sites and hospitals within Australia and is subject to stringent regulatory oversight to protect human health and the environment. Submissions to the Regulator regarding this application should be made by 9 December 2024, referencing DIR-206, and should address any concerns related to the protection of human health and safety and the environment. The Act does not specify exclusions or exemptions for this particular clinical trial, but it does provide a framework for the Regulator to assess and manage risks associated with gene technology activities. The scope of application is further extended through subordinate instruments which may detail specific procedural requirements and conditions for the conduct of clinical trials involving genetically modified organisms.

Key Provisions

The main operative sections of this legislation focus on the clinical trial application submitted by the Western Sydney Local Health District (WSLHD) for the use of genetically modified bacteriophages to treat mycobacterial infections (section 1). The application includes a proposed Risk Assessment and Risk Management Plan (RARMP), which is a critical document in evaluating the safety and environmental impact of the trial (section 2). This clinical trial, if approved, will be conducted at selected Australian clinical trial sites and hospitals, with a minimum of three participants over a five-year period (section 3). The obligations imposed by this Act require WSLHD to submit a comprehensive application detailing the clinical trial’s objectives, methodology, and potential risks. The application must include the RARMP, which outlines how the risks to human health and the environment will be assessed and managed (section 4). Additionally, the Act mandates that the Gene Technology Regulator will evaluate the application based on the information provided, including any public submissions received during the consultation period (section 5). The Regulator’s assessment will consider both the scientific merits of the trial and the potential implications for public health and the environment. The legislation also specifies the timeframe for public submissions, requiring interested parties to submit their comments by 9 December 2024 (section 6). Submissions must reference the application number DIR-206 to ensure they are considered in the decision-making process (section 7). Furthermore, the Regulator is required to make a decision on whether to issue the licence for the clinical trial, taking into account the information provided in the application and the feedback from the consultation period (section 8). In terms of breaches and penalties, the Act does not explicitly outline specific offences or penalties for non-compliance with the clinical trial application process. However, any breaches of the conditions set forth in the licence, if issued, could potentially lead to enforcement actions, including fines or other civil or criminal consequences under related legislation (section 9). The exact penalties would depend on the nature and severity of the breach, as well as the provisions of other applicable laws.